{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:34:48Z","timestamp":1790001288296,"version":"4.0.1"},"publisher-location":"Berlin, Heidelberg","reference-count":63,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642701429","type":"print"},{"value":"9783642701405","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1985]]},"DOI":"10.1007\/978-3-642-70140-5_19","type":"book-chapter","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T18:06:39Z","timestamp":1319565999000},"page":"145-159","source":"Crossref","is-referenced-by-count":18,"title":["Pathophysiology of L-Dopa-Induced Abnormal Involuntary Movements"],"prefix":"10.1007","author":[{"given":"Y.","family":"Agid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Javoy-Agid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"19_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/245150a0","volume":"245","author":"Y Agid","year":"1973","unstructured":"Agid Y, Javoy F, Glowinski J (1973) Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nature 245: 150\u2013151","journal-title":"Nature"},{"key":"19_CR2","first-page":"401","volume-title":"Advances in neurology","author":"Y Agid","year":"1979","unstructured":"Agid Y, Bonnet AM, Signoret JL, Lhermitte F (1979) Clinical, pharmacological and biochemical approach of \u201conset and end-of-dose\u201d dyskinesias. In: Poirier LJ, Sourkes TL, Bedard PJ (eds) Advances in neurology, vol 24. Raven, New York, pp 401 \u2013409"},{"key":"19_CR3","first-page":"475","volume":"1","author":"A Barbeau","year":"1976","unstructured":"Barbeau A (1976) Neurological and psychiatric side-effects of L-DOPA. Pharmacol Ther 1: 475\u2013494","journal-title":"Pharmacol Ther"},{"key":"19_CR4","first-page":"203","volume-title":"Parkinsons disease","author":"A Barbeau","year":"1971","unstructured":"Barbeau A, Mars H, Gillio-Joffroy L (1971) Adverse clinical side-effects of levodopa therapy. In: McDowell FH, Markham CH (eds) Parkinson\u2019s disease. Davis, Philadelphia, pp 203\u2013237"},{"key":"19_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415\u2013455","journal-title":"J Neurol Sci"},{"key":"19_CR6","volume-title":"Greenfields neuropathology","author":"W Blackwood","year":"1976","unstructured":"Blackwood W, Corsellis JAN (1976) Greenfields neuropathology, 3rd edn. Arnold, London","edition":"3"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0014-2999(84)90238-3","volume":"99","author":"B Bokobza","year":"1984","unstructured":"Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) 3H-spiperone binding, dopamine and HVA concentrations in Parkinson\u2019s disease and supranuclear palsy. Eur J Pharmacol 99: 167\u2013175","journal-title":"Eur J Pharmacol"},{"key":"19_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/289537a0","volume":"289","author":"A Cheramy","year":"1981","unstructured":"Cheramy A, Laviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289: 537","journal-title":"Nature"},{"key":"19_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1126\/science.877576","volume":"197","author":"I Creese","year":"1977","unstructured":"Creese I, Burt DR, Snyder SH (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197: 596\u2013598","journal-title":"Science"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.21.10.1023","volume":"21","author":"AD Ericsson","year":"1971","unstructured":"Ericsson AD, Wertman BG, Duffy KM (1971) Reversal of the reserpine syndrome with L-DOPA metabolites in reserpinized rats. Neurology 21: 1023\u20131029","journal-title":"Neurology"},{"key":"19_CR11","first-page":"173","volume-title":"Monoamines, noyaux gris centraux et syndrome de Parkinson. Symposium Bel Air IV","author":"R Escourolle","year":"1970","unstructured":"Escourolle R, De Recondo J, Gray F (1970) Etude anatomopathologique de syndromes parkinsoniens. In: De Ajuriaguerra J (ed) Monoamines, noyaux gris centraux et syndrome de Parkinson. Symposium Bel Air IV. Masson, Paris, pp 173\u2013229"},{"key":"19_CR12","first-page":"277","volume":"97","author":"S Fahn","year":"1972","unstructured":"Fahn S, David E (1972) Oro-faciaL-lingual dyskinesia due to anticholinergic medication. Trans Am Neurol Assoc 97: 277\u2013279","journal-title":"Trans Am Neurol Assoc"},{"key":"19_CR13","first-page":"178","volume-title":"Advances in Parkinsonism","author":"IJ Farley","year":"1976","unstructured":"Farley IJ, Hornykiewicz O (1976) Noradrenaline in subcortical brain regions of patients with Parkinson\u2019s disease and control subjects. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Roche, Basel, pp 178\u2013185"},{"key":"19_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1600-0404.1977.tb01456.x","volume":"56","author":"C Feuerstein","year":"1977","unstructured":"Feuerstein C, Serre F, Gavend M, Pellat J, Perret J, Tanche M (1977) Plasma O-Methyldopa in levodopa-induced dyskinesias: a bioclinical investigation. Acta Neurol Scand 56: 508\u2013524","journal-title":"Acta Neurol Scand"},{"key":"19_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0014-2999(81)90122-9","volume":"76","author":"C Feuerstein","year":"1981","unstructured":"Feuerstein C, Demenge P, Barrette G, Silice C, Guerin B, Mouchet P (1981) Long-term effects of nigrostriatal denervation on 3H-haloperidol binding. Eur J Pharmacol 76: 457\u2013460","journal-title":"Eur J Pharmacol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1212\/WNL.33.11.1489","volume":"33","author":"O Gershanik","year":"1983","unstructured":"Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptors activation. Neurology 33: 1489\u20131492","journal-title":"Neurology"},{"key":"19_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0014-2999(84)90587-9","volume":"98","author":"M Herrera-Marschitz","year":"1984","unstructured":"Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98: 165\u2013176","journal-title":"Eur J Pharmacol"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","volume":"18","author":"O Hornykiewicz","year":"1966","unstructured":"Hornykiewicz O (1966) Dopamine (3-Hydroxytyramine) and brain function. Pharmacol Rev 18: 925\u2013964","journal-title":"Pharmacol Rev"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1212\/WNL.30.12.1326","volume":"30","author":"F Javoy-Agid","year":"1980","unstructured":"Javoy-Agid F, Agid Y (1980) Is the mesocortical dopaminergic system involved in Parkinson\u2019s disease? Neurology 30: 1326\u20131330","journal-title":"Neurology"},{"key":"19_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1471-4159.1981.tb04672.x","volume":"37","author":"F Javoy-Agid","year":"1982","unstructured":"Javoy-Agid F, Ploska A, Agid Y (1982a) Microtopography of TH, CAT, and GAD activity in the substantia nigra and ventral tegmental area of control and parkinsonian human brain. J Neurochem 37: 1218\u20131227","journal-title":"J Neurochem"},{"key":"19_CR21","first-page":"151","volume-title":"Gilles de la Tourette syndrome. Adv Neurol","author":"F Javoy-Agid","year":"1982","unstructured":"Javoy-Agid F, Ruberg M, Taquet H, Studler JM, Lloyd KG, Garbarg M, Llorens-Cortes C, Grouselle D, Agid Y (1982b) Biochemical neuroanatomy of the human substantia nigra (pas compacta) in normal and parkinsonian subject. In: Friedhoff AJ, Chase TN (eds) Gilles de la Tourette syndrome. Adv Neurol 35: 151\u2013163"},{"key":"19_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0143-4179(83)90029-X","volume":"3","author":"F Javoy-Agid","year":"1983","unstructured":"Javoy-Agid F, Grouselle D, Tixier-Vidal A, Agid Y (1983) Thyrotropin releasing hormone in brain of patients with Parkinson\u2019s disease. Neuropeptides 3: 405\u2013410","journal-title":"Neuropeptides"},{"key":"19_CR23","first-page":"189","volume-title":"Parkinson-specific motor and mental disorders, role of the pallidum: pathophysiological, biochemical, and therapeutic aspects. Adv Neurol","author":"F Javoy-Agid","year":"1984","unstructured":"Javoy-Agid F, Ruberg M, Taquet H, Bokobza B, Agid Y, Gaspar P, Berger B, N\u2019Guyen- Legros J, Alvarez C, Gray F, Hauw JJ, Scatton B, Rouquier L (1984a) Biochemical neuropathology of Parkinson disease. In: Hassler RG, Christ JF (eds) Parkinson-specific motor and mental disorders, role of the pallidum: pathophysiological, biochemical, and therapeutic aspects. Adv Neurol 40: 189\u2013198"},{"key":"19_CR24","first-page":"35","volume-title":"Catecholamines: Neuropharmacology and central nervous system \u2014 Therapeutic aspects","author":"F Javoy-Agid","year":"1984","unstructured":"Javoy-Agid F, Taquet H, Cesselin F, Epelbaum J, Grouselle D, Mauborgne A, Studler JM, AgidY (1984b) Neuropeptides in Parkinson\u2019s disease. In: Usdin E (ed) Catecholamines: Neuropharmacology and central nervous system \u2014 Therapeutic aspects. Liss, New York, pp 35\u201342"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.34.5.672","volume":"34","author":"F Javoy-Agid","year":"1984","unstructured":"Javoy-Agid F, Ruberg M, Pique L, Bertagna X, Taquet H, Studler JM, Cesselin F, Epelbaum J, Agid Y (1984c) Biochemistry of the hypothalamus in Parkinson disease. Neurology 34: 672\u2013676","journal-title":"Neurology"},{"key":"19_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/jnnp.37.4.427","volume":"37","author":"HL Klawans","year":"1974","unstructured":"Klawans HL, Weiner WJ (1974) Attempted use of haloperidol in the treatment of L-DOPA induced dyskinesias. J Neurol Neurosurg Psychiatry 37: 427\u2013430","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR27","first-page":"105","volume-title":"Dopaminergic mechanisms. Adv Neurol","author":"HL Klawans","year":"1975","unstructured":"Klawans HL, Crossett P, Dana N (1975) Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-DOPA-induced dyskinesias. In: Calne D, Chase TN, Barbeau A (eds) Dopaminergic mechanisms. Adv Neurol 9: 105\u2013112"},{"key":"19_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-2999(70)90272-4","volume":"10","author":"I Kuruma","year":"1970","unstructured":"Kuruma I, Bartholini G, Pletscher A (1970) L-DOPA induced accumulation of 3-O-methyL-DOPA in brain and heart. Eur J Pharmacol 10: 189\u2013192","journal-title":"Eur J Pharmacol"},{"key":"19_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/273059a0","volume":"273","author":"T Lee","year":"1978","unstructured":"Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson\u2019s disease. Nature 273: 59","journal-title":"Nature"},{"key":"19_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/0006-8993(81)90484-4","volume":"212","author":"T Lee","year":"1981","unstructured":"Lee T, Seeman P, Hornykiewicz O, Bilbao J, Tourtellotte WW (1981) Parkinson\u2019s disease: low density and presynaptic location of D3 receptors. Brain Res 212: 494","journal-title":"Brain Res"},{"issue":"5","key":"19_CR31","first-page":"297","volume":"133","author":"F Lhermitte","year":"1977","unstructured":"Lhermitte F, Agid Y, Signoret JL, Studier JM (1977a) Les dyskinesies de \u201cd\u00e9but et fin de dose\u201d provoqu\u00e9es par la L-DOPA. Rev Neurol 133, 5: 297\u2013308","journal-title":"Rev Neurol"},{"key":"19_CR32","first-page":"445","volume":"133","author":"F Lhermitte","year":"1977","unstructured":"Lhermitte F, Agid Y, Feuerstein C, Serre F, Signoret JL, Studier JM, Bonnet AM (1977b) Mouvements anormaux provoqu\u00e9es par la L-DOPA dans la maladie de Parkinson: corr\u00e9lation avec les concentrations plasmiques de DOPA et de O-m\u00e9thy L-DOPA. Rev Neurol 133: 445\u2013454","journal-title":"Rev Neurol"},{"key":"19_CR33","first-page":"9","volume":"53","author":"F Lhermitte","year":"1977","unstructured":"Lhermitte F, Signoret JL, Agid Y (1977c) Etude des effets d\u2019une mol\u00e9cule originale le Tiapride, dans le traitement des mouvements anormaux d\u2019origine extra-pyramidale. Sem Hop Paris 53: 9\u201315","journal-title":"Sem Hop Paris"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archneur.1978.00500290007002","volume":"35","author":"F Lhermitte","year":"1978","unstructured":"Lhermitte F, Agid Y, Signoret JL (1978) Onset and end-of-dose levodopa-induced dyskinesias, possible treatment by increasing the daily doses of levodopa. Arch Neurol 35: 261\u2013263","journal-title":"Arch Neurol"},{"key":"19_CR35","first-page":"96","volume-title":"Movement disorder","author":"CD Marsden","year":"1982","unstructured":"Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson\u2019s disease \u2014 clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorder. Butterworth Scientific, London, pp 96\u2013122"},{"key":"19_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0006-8993(83)90403-1","volume":"268","author":"A Mauborgne","year":"1983","unstructured":"Mauborgne A, Javoy-Agid F, Legrand JC, AgidY, Cesselin F (1983) Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res 268: 167\u2013170","journal-title":"Brain Res"},{"issue":"1","key":"19_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197001012820102","volume":"282","author":"I Mena","year":"1970","unstructured":"Mena I, Court J, Fuenzalida S, Papavasiliou PS, Cotzias GC (1970) Modification of chronic manganese poisoning treatment with L-DOPA or 5-OH-tryptophan N Engl J Med 282, 1: 5\u20139","journal-title":"N Engl J Med"},{"key":"19_CR38","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp.34.6.668","volume":"34","author":"RJ Mones","year":"1971","unstructured":"Mones RJ, Elizan TS, Seigel G (1971) Analysis of L-DOPA induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 34: 668\u2013673","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR39","first-page":"231","volume":"46","author":"MD Muenter","year":"1971","unstructured":"Muenter MD, Tyce GM (1971) L-DOPA therapy of Parkinson\u2019s disease: plasma L-DOPA concentration, therapeutic response and side effects. Mayo Clin Proc 46: 231\u2013239","journal-title":"Mayo Clin Proc"},{"key":"19_CR40","first-page":"389","volume":"47","author":"MD Muenter","year":"1972","unstructured":"Muenter MD, Sharpless NS, Tyce GM (1972) Plasma 3-O-methyL-DOPA in L-DOPA therapy in Parkinson\u2019s disease. Mayo Clin Proc 47: 389\u2013395","journal-title":"Mayo Clin Proc"},{"key":"19_CR41","first-page":"163","volume":"52","author":"MD Muenter","year":"1977","unstructured":"Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (\u201cI-D-I\u201d and \u201cD-I-D\u201d) in response to L-DOPA therapy for Parkinson\u2019s disease. Mayo Clin Proc 52: 163\u2013174","journal-title":"Mayo Clin Proc"},{"key":"19_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/0006-2944(78)90036-4","volume":"19","author":"T Nagatsu","year":"1978","unstructured":"Nagatsu T, Kanamori T, Kato T, Iikuza R, Narabayashi H (1978) Dopamine stimulated adenylate cyclase activity in the human brain: changes in Parkinsonism. Biochem Med 19: 360\u2013365","journal-title":"Biochem Med"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0022-3565(25)28745-6","volume":"175","author":"C Ohye","year":"1970","unstructured":"Ohye C, Bouchard R, Boucher R, Poirier LJ (1970) Spontaneous activity of the putamen after chronic interruption of the dopaminergic pathway: effect of L-DOPA. J Pharm Exp Ther 175: 700\u2013708","journal-title":"J Pharm Exp Ther"},{"issue":"5693","key":"19_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1136\/bmj.1.5693.400","volume":"1","author":"MJT Peaston","year":"1970","unstructured":"Peaston MJT, Bianchine JR (1970) Metabolic studies and clinical observations during L-DOPA treatment of Parkinson\u2019s disease. Br Med J 1, 5693: 400\u2013403","journal-title":"Br Med J"},{"key":"19_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/brain\/89.1.37","volume":"89","author":"LJ Poirier","year":"1966","unstructured":"Poirier LJ, Sourkes TL, Bouvier G, Boucher R, Carabin S (1966) Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain 89: 37\u201352","journal-title":"Brain"},{"key":"19_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0022-510X(79)90021-2","volume":"43","author":"M Quik","year":"1979","unstructured":"Quik M, Spokes EG, McKay AVP, Bannister R (1979) Alterations in 3H-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in Shy-Drager syndrome and Parkinson\u2019s disease. J Neurol Sci 43: 429","journal-title":"J Neurol Sci"},{"key":"19_CR47","first-page":"94","volume":"10","author":"A Reches","year":"1981","unstructured":"Reches A, Fahn S (1981) O-methyldopa interferes with striatal utilization of levodopa. Ann Neurol 10: 94\u201395","journal-title":"Ann Neurol"},{"key":"19_CR48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0024-3205(77)90514-8","volume":"21","author":"TD Reisine","year":"1977","unstructured":"Reisine TD, Fields JZ, Stern LZ, Johnson PC, Bird ED, Spokes E, Schreiner PS, Enna SJ (1977) Neurotransmitter receptor alterations in Parkinson\u2019s disease. Life Sci 21: 335","journal-title":"Life Sci"},{"key":"19_CR49","unstructured":"Riederer P, Ransch WD, Birkmayer W, Jellinger K, Danielczyk W (1978) Dopamine sensitive adenylate cyclase activity in the caudate nucleus and metabolic encephalopathies. J Neural Transm [Suppl 14]: 153"},{"key":"19_CR50","first-page":"93","volume-title":"Parkinsons disease. Current Progress, Problems and Management","author":"UK Rinne","year":"1980","unstructured":"Rinne UK, Koskinen V, Lonnberg P (1980) Neurotransmitter receptors in the parkinsonian brain. In: Rinne UK, Klinger M, Stamm M (eds) Parkinson\u2019s disease. Current Progress, Problems and Management. Elsevier, Amsterdam, pp 93"},{"key":"19_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/0006-8993(76)90293-6","volume":"112","author":"E Rinvik","year":"1976","unstructured":"Rinvik E, Grofova I, Ottersen OP (1976) Demonstration of nigrotectal and nigroreticular projections in the cat by axonal transport of proteins. Brain Res 112: 388\u2013394","journal-title":"Brain Res"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/archneur.1977.00500160042007","volume":"34","author":"L Rivera-Calimlin","year":"1977","unstructured":"Rivera-Calimlin L, Tandron D, Anderson F, Joynt R (1977) The clinical picture and plasma levodopa metabolite profile of parkinsonism non responders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 34: 228\u2013232","journal-title":"Arch Neurol"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.22.11.1122","volume":"22","author":"JF Sassin","year":"1972","unstructured":"Sassin JF, Taub S, Weitzman ED (1972) Hyperkinesia and changes in behavior produced in normal monkeys by L-DOPA. Neurology 22: 1122\u20131125","journal-title":"Neurology"},{"key":"19_CR54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","volume":"275","author":"B Scatton","year":"1983","unstructured":"Scatton B, Javoy-Agid F, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease. Brain Res 275: 321\u2013328","journal-title":"Brain Res"},{"key":"19_CR55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0031-6997(25)06839-5","volume":"3","author":"P Seeman","year":"1980","unstructured":"Seeman P (1980) Brain dopamine receptors. Pharm Rev 3: 229\u2013313","journal-title":"Pharm Rev"},{"key":"19_CR56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF01250323","volume":"44","author":"M Shibuya","year":"1979","unstructured":"Shibuya M (1979) Dopamine sensitive adenylate cyclase activity in the striatum of Parkinson\u2019s disease. J Neurol Transm 44: 287","journal-title":"J Neurol Transm"},{"issue":"2","key":"19_CR57","first-page":"103","volume":"122","author":"J Sigwald","year":"1970","unstructured":"Sigwald J, Raymondeaud C (1970) Les mouvements anormaux observ\u00e9s au cours du traitement de la maladie de Parkinson par la L-DOPA. Rev Neurol 122, 2: 103\u2013112","journal-title":"Rev Neurol"},{"key":"19_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0006-8993(83)90071-9","volume":"280","author":"H Taquet","year":"1983","unstructured":"Taquet H, Javoy-Agid F, Hamon M, Legrand JC, Agid Y, Cesselin F (1983) Parkinson\u2019s disease affects differently Met5 and Leu5-enkephalin in the human brain. Brain Res 280: 379\u2013382","journal-title":"Brain Res"},{"key":"19_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/jnnp.38.4.331","volume":"38","author":"D Tarsy","year":"1975","unstructured":"Tarsy D, Parkes JD, Marsden CD (1975) Metoclopramide and pimozide in Parkinson\u2019s disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 38: 331\u2013335","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR60","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0140-6736(75)92293-X","volume":"1","author":"ES Tolosa","year":"1975","unstructured":"Tolosa ES, Martin WE, Cohen HP (1975) Dyskinesias during levodopa therapy. Lancet 1: 1381\u20131382","journal-title":"Lancet"},{"key":"19_CR61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced-de-generation of the nigrostriatal dopamine system. Acta Physiol Scand [Suppl] 367: 69\u201393","journal-title":"Acta Physiol Scand [Suppl]"},{"key":"19_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0024-3205(75)90248-9","volume":"17","author":"LA Wade","year":"1975","unstructured":"Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-DOPA at the blood brain barrier. Life Sci 17: 131\u2013136","journal-title":"Life Sci"},{"key":"19_CR63","first-page":"101","volume-title":"L-DOPA and parkinsonism","author":"MD Yahr","year":"1970","unstructured":"Yahr MD (1970) Abnormal involuntary movements induced by dopa: clinical aspects. In: Barbeau A, McDowell FH (eds) L-DOPA and parkinsonism. Davis, Philadelphia, pp 101\u2013108"}],"container-title":["Psychopharmacology Supplementum","Dyskinesia"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-70140-5_19.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:11:14Z","timestamp":1741853474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-70140-5_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985]]},"ISBN":["9783642701429","9783642701405"],"references-count":63,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-70140-5_19","relation":{},"ISSN":["0931-6795"],"issn-type":[{"value":"0931-6795","type":"print"}],"subject":[],"published":{"date-parts":[[1985]]}}}